Market
What will be the cost reduction percentage in IVF using GametoGen's iPSC technology by end of 2025?
2
Resolution / Starting Odds
Less than 20% • 25%
20% to 39% • 25%
40% to 59% • 25%
60% or more • 25%
Industry reports or studies published in reputable journals
Story
GametoGen Achieves First Live Birth Using iPSC Technology in IVF, Reducing Hormone Injections by 80% and Treatment to Three Days
Dec 16, 2024, 04:09 PM
GametoGen, a next-generation IVF startup, has announced the first successful live birth using its innovative technology, which utilizes induced pluripotent stem cell (iPSC)-derived ovarian cells. This groundbreaking achievement marks a significant milestone in reproductive technology, as the company claims it is the first human birth resulting from iPSC technology. The new method reportedly replaces 80% of the hormone injections typically required in traditional IVF and shortens treatment cycles to just three days. The announcement has garnered attention for its potential to revolutionize access to IVF and improve outcomes for families seeking fertility assistance.
View original story
Similar markets
Moderate Improvement • 25%
Significant Improvement • 25%
Harmful Effects • 25%
No Improvement • 25%
Q3 2025 • 25%
Q2 2025 • 25%
Q1 2025 • 25%
Q4 2025 • 25%
31% or more • 25%
21-30% • 25%
11-20% • 25%
0-10% • 25%
Regenerative Medicine • 25%
Anti-Aging Treatments • 25%
Cancer Therapy • 25%
Other • 25%
Less than 10% • 25%
More than 30% • 25%
10% to 20% • 25%
20% to 30% • 25%
75% to 80% • 25%
Less than 50% • 25%
50% to 74% • 25%
More than 80% • 25%
Successful with no safety issues • 25%
Successful with minor safety issues • 25%
Unsuccessful due to safety issues • 25%
Inconclusive results • 25%
Clinics face criminal charges • 25%
Clinics cleared of wrongdoing • 25%
Clinics face fines • 25%
Clinics face license suspensions • 25%
More than 50 labs • 25%
20-30 labs • 25%
41-50 labs • 25%
31-40 labs • 25%